Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens

CD38 is expressed in several types of non-Hodgkin lymphoma (NHL) and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti-CD38 antibody approved for the treatment of relapsed/refractory (R/R) multiple myeloma (MM). It has also demonstrated clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Vidal-Crespo, Anna, Matas-Céspedes, Alba, Rodriguez, Vanina, Rossi, Cédric, Valero, Juan G., Serrat, Neus, Sanjuan-Pla, Alejandra, Menéndez, Pablo, Roué, Gaël, López-Guillermo, Armando, Giné, Eva, Campo, Elías, Colomer, Dolors, Bezombes, Christine, van Bueren, Jeroen Lammerts, Chiu, Christopher, Doshi, Parul, Pérez-Galán, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109732/
https://www.ncbi.nlm.nih.gov/pubmed/31296574
http://dx.doi.org/10.3324/haematol.2018.211904

Ejemplares similares

Ejemplares similares